Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer

BACKGROUND: Overexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 15–23% of breast cancers and these cancers are classified as HER2-positive breast cancer. Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer and has improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Tatsuaki, Yamamoto, Hiromasa, Kanzaki, Hirotaka, Suzawa, Ken, Yoshioka, Takahiro, Tomida, Shuta, Cui, Xiaojiang, Murali, Ramachandran, Namba, Kei, Sato, Hiroki, Torigoe, Hidejiro, Watanabe, Mototsugu, Shien, Kazuhiko, Soh, Junichi, Asano, Hiroaki, Tsukuda, Kazunori, Kitamura, Yoshihisa, Miyoshi, Shinichiro, Sendo, Toshiaki, Toyooka, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291431/
https://www.ncbi.nlm.nih.gov/pubmed/28158234
http://dx.doi.org/10.1371/journal.pone.0171356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291431/
https://www.ncbi.nlm.nih.gov/pubmed/28158234
http://dx.doi.org/10.1371/journal.pone.0171356

Ejemplares similares